User login
A pediatric dosing chart for the influenza drug oseltamivir (Tamiflu) sent by Roche Laboratories Inc. to health care providers last November contained an error and should have indicated a standard dosage of once daily—rather than twice daily—for 10 days, according to a Dec. 26 letter from the company.
The erroneous chart, titled “Standard Dosage of the Tamiflu Oral Suspension for Prophylaxis of Influenza in Pediatric Patients,” had accompanied a Nov. 13 letter announcing that reports of self-injury and delirium in patients taking Tamiflu had been added to the precautions section of the product's package insert.
The company urges medical professionals to discard the incorrect chart.
The letter from Roche noted that none of the Tamiflu on the market contains package inserts with the incorrect dosage chart.
Complete prescribing information is available online at www.rocheusa.com/products/tamiflu/pi.pdf
Questions can be directed to Roche at 800–526–6367.
A pediatric dosing chart for the influenza drug oseltamivir (Tamiflu) sent by Roche Laboratories Inc. to health care providers last November contained an error and should have indicated a standard dosage of once daily—rather than twice daily—for 10 days, according to a Dec. 26 letter from the company.
The erroneous chart, titled “Standard Dosage of the Tamiflu Oral Suspension for Prophylaxis of Influenza in Pediatric Patients,” had accompanied a Nov. 13 letter announcing that reports of self-injury and delirium in patients taking Tamiflu had been added to the precautions section of the product's package insert.
The company urges medical professionals to discard the incorrect chart.
The letter from Roche noted that none of the Tamiflu on the market contains package inserts with the incorrect dosage chart.
Complete prescribing information is available online at www.rocheusa.com/products/tamiflu/pi.pdf
Questions can be directed to Roche at 800–526–6367.
A pediatric dosing chart for the influenza drug oseltamivir (Tamiflu) sent by Roche Laboratories Inc. to health care providers last November contained an error and should have indicated a standard dosage of once daily—rather than twice daily—for 10 days, according to a Dec. 26 letter from the company.
The erroneous chart, titled “Standard Dosage of the Tamiflu Oral Suspension for Prophylaxis of Influenza in Pediatric Patients,” had accompanied a Nov. 13 letter announcing that reports of self-injury and delirium in patients taking Tamiflu had been added to the precautions section of the product's package insert.
The company urges medical professionals to discard the incorrect chart.
The letter from Roche noted that none of the Tamiflu on the market contains package inserts with the incorrect dosage chart.
Complete prescribing information is available online at www.rocheusa.com/products/tamiflu/pi.pdf
Questions can be directed to Roche at 800–526–6367.